Explanipedia

Immune Checkpoint Inhibitor Therapy and Acute Coronary Syndrome: A Review of Mechanisms and Management Open

Rachel S Saganty, Orly Leiva, Elizabeth Hutchins, Ashley Stein-Merlob, Eric H. Yang · 2025

Immune checkpoint inhibitor (ICI) therapy is a class of immune‐activating therapies that has revolutionized the treatment of various cancers over the past decade. With expanding clinical indications of this drug class, understanding the sh…

Association between Active Cancer and Risk of Thrombotic and Cardiovascular Outcomes in Outpatients with COVID-19: A CORONA-VTE Network Analysis Open

Bridget McGonagle, Christie Greason, Darsiya Krishnathasan, Giovanni Scimeca, Antoine Bejjani , et al. · 2025

Coronavirus disease 2019 (COVID-19) and active cancer are each independently associated with excess risk of thrombotic and cardiovascular events. However, data are limited regarding the risk of these events in outpatients with active cance…

Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms Open

Orly Leiva, Olivia Liu, Anthony Kanelidis, Stanley Swat, L. Gozdecki , et al. · 2025

Patients with myeloproliferative neoplasms (MPNs) are at increased risk for cardiovascular disease. Although thrombosis is a well-recognized complication, emerging evidence indicates that nonthrombotic conditions, including heart failure (…

Catheter‐Based Therapies for Patients Hospitalized With Pulmonary Embolism and Secondary Diagnosis of Cardiac Arrest Open

Orly Leiva, Robert Zhang, Carlos L. Alviar, Sripal Bangalore · 2025

Background Pulmonary embolism (PE) is can present with cardiac arrest. Catheter‐based therapies (CBT) provide rapid reperfusion for patients with PE, though their effect on outcomes of patients with PE and cardiac arrest are not well known…

Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms Open

Orly Leiva, Steven Soo, Olivia Liu, Nathaniel R. Smilowitz, Harmony R. Reynolds , et al. · 2025

Pulmonary hypertension (PH) is a frequent complication of Philadelphia-negative myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). However, its prognostic significa…

Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes Open

Joan How, Orly Leiva, Robert Redd, Anna E. Marneth, Daniel J. DeAngelo , et al. · 2025

In-hospital and readmission outcomes of patients with cancer admitted for pulmonary embolism treated with or without catheter-based therapy Open

Orly Leiva, Eric H. Yang, Rachel Rosovsky, Carlos L. Alviar, Sripal Bangalore · 2024

Among patients with cancer with intermediate or high-risk PE, CBT was associated with lower in-hospital death and 90-day readmission. CBT was also associated with decreased risk of index hospitalization major bleeding compared with systemi…

C-68 | Readmission Outcomes in those with Same Day Discharge After Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction Open

Johanna Lerner, Orly Leiva, Sripal Bangalore, Sunil V. Rao · 2024

Same day discharge (SDD) following elective percutaneous coronary intervention (PCI) is safe, increases patient satisfaction, and may provide an economic advantage to hospitals. Outcomes associated with SDD after PCI for NSTEMI are not wel…

Low absolute risk of thrombotic and cardiovascular events in outpatient pregnant women with COVID-19 Open

Behnood Bikdeli, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Julia Davies , et al. · 2024

Thrombotic and cardiovascular events are rare among outpatients with COVID-19. Although a higher event rate among outpatient pregnant women cannot be excluded, the absolute event rates are low and do not warrant population-wide cardiovascu…

Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications Open

Orly Leiva, William Beaty, Steven Soo, Manyoo Agarwal, Eric H. Yang · 2024

Advances in cancer therapies have improved oncologic outcomes but can potentially expose patients to risk of cardiovascular toxicity. While left ventricular (LV) dysfunction is a well-known cardiotoxicity of cancer therapy. Pulmonary hyper…

Reply Open

Orly Leiva, Gabriela S. Hobbs, Sripal Bangalore · 2023

In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and heart failure: Insights from the National Readmissions Database Open

Orly Leiva, Jose Alvarez‐Cardona, Joan How, Andrew M. Brunner, Gabriela S. Hobbs · 2023

Among patients hospitalized for HF, MPN was associated with increased risk of in-hospital death, and 90-day CV-related readmissions (driven primarily by thrombotic readmissions). Further investigation is needed in order to improve outcomes…

Outcomes of Patients With Cancer With Myocardial Infarction-Associated Cardiogenic Shock Managed With Mechanical Circulatory Support Open

Orly Leiva, Richard K. Cheng, Sunil Pauwaa, Jason N. Katz, Jose Alvarez‐Cardona , et al. · 2023

Among patients with AMI-CS managed with tMCS, cancer is becoming increasingly frequent and associated with increased risk of major bleeding, although there was no difference in in-hospital death. Further studies are needed to further chara…

Acute myocardial infarction in von Willebrand disease: characteristics and outcomes Open

Orly Leiva, Jean M. Connors, Nathan T. Connell, Jeffrey S. Berger · 2023

Among patients admitted with AMI, VWD was associated with higher risk of 90-day readmission for bleeding but not any-cause and arterial thrombosis-related readmissions. Further studies are needed to balance bleeding and thrombotic risks po…

P1029: JAK2-CHIP IS ASSOCIATED WITH SIMILAR RISK OF CARDIOVASCULAR DISEASE AS JAK2-MPN Open

Jeremy D. Grevet, Orly Leiva, Gabriela S. Hobbs, Joan How · 2023

Topic: 16. Myeloproliferative neoplasms - Clinical Background: Clonal hematopoiesis of indeterminate potential (CHIP) is defined as the presence of an expanded somatic blood cell clone in persons without a known hematologic disorder at a v…

Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons Open

Orly Leiva, Brenda Garcia, Gabriela S. Hobbs · 2023

"Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population Open

Orly Leiva, Uazman Alam, Isaac Bohart, Eric H. Yang · 2023

Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction Open

Orly Leiva, Yuhe Xia, Emaad Siddiqui, Gabriela S. Hobbs, Sripal Bangalore · 2023

Among patients hospitalized with AMI, patients with MPNs have a lower risk of in-hospital death or CA compared with patients without MPNs, although they have a higher risk of bleeding. More investigation is needed in order to improve post-…

Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms Open

Orly Leiva, Andrew Jenkins, Rachel Rosovsky, Rebecca Karp Leaf, Katayoon Goodarzi , et al. · 2023

Patients with myeloproliferative neoplasms (MPNs) are at increased risk of cardiovascular disease (CVD), including acute coronary syndrome (ACS). However, data on long-term outcomes of patients with MPN who have had ACS and risk factors fo…

Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study Open

Behnood Bikdeli, Candrika D. Khairani, Darsiya Krishnathasan, Antoine Bejjani, Andre Armero , et al. · 2023

Atrial fibrillation and cancer: Two peas in a pod Open

Orly Leiva · 2023

Off-Target Effects of Cancer Therapy on Development of Therapy-Induced Arrhythmia: A Review Open

Orly Leiva, Isaac Bohart, Tania Ahuja, David Park · 2023

Background: Advances in cancer therapeutics have improved overall survival and prognosis in this patient population; however, this has come at the expense of cardiotoxicity including arrhythmia. Summary: Cancer and its therapies are associ…

Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation Open

Orly Leiva, Andrew Jenkins, Rachel Rosovsky, Rebecca Karp Leaf, Katayoon Goodarzi , et al. · 2022

Patients with myeloproliferative neoplasms and COVID‐19 have increased rates of arterial thrombosis Open

Orly Leiva, Umberto Campia, Julia Snyder, Briana M. Barns, Samantha Rizzo , et al. · 2022

Among patients with COVID-19, MPN patients had higher risk of arterial thrombosis but not VTE, bleeding, and death compared with non-MPN patients. Larger studies are needed to confirm our findings given the limited sample size.

Cardiovascular Disease in Myeloproliferative Neoplasms Open

Orly Leiva, Gabriela S. Hobbs, Katya Ravid, Peter Libby · 2022

Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling p…

Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations Open

Jonathan D. Ravid, Orly Leiva, Vipul C. Chitalia · 2022

Acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection continues to be a worldwide public health crisis. Among the several severe manifestations of this disease, thrombotic processes drive the catastrophic organ failure and mortal…

Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis Open

Orly Leiva, Duaa AbdelHameid, Jean M. Connors, Christopher P. Cannon, Deepak L. Bhatt · 2021

Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging evidence suggests common mechanisms between cancer and cardiovascular disease, including atrial fibrillation and atherosclerosis. With advances in canc…

Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19 Open

Orly Leiva, Umberto Campia, Julia Snyder, Briana M. Barns, Samantha Rizzo , et al. · 2021

Background: Coronavirus disease-2019 (COVID-19) is an inflammatory, multisystem infectious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-COV-2) and is associated with increased risk of thrombosis, particularly amo…

Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations Open

Orly Leiva, Olesya Baker, Andrew Jenkins, Andrew M. Brunner, Hanny Al‐Samkari , et al. · 2021

In this cohort study, thrombosis was common in patients with HES and was significantly associated with increased risk of death.

Natural language processing for the assessment of cardiovascular disease comorbidities: The <span>cardio‐Canary</span> comorbidity project Open

Adam N. Berman, David Biery, Curtis Ginder, Olivia Hulme, Daniel P. Marcusa , et al. · 2021

Objective: Accurate ascertainment of comorbidities is paramount in clinical research. While manual adjudication is labor‐intensive and expensive, the adoption of electronic health records enables computational analysis of free‐text documen…

Orly Leiva YOU? Author Swipe